This funding opportunity supports the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, monitoring, and treatment response prediction. Applicants may submit biphasic UH2/UH3 or standalone UH3 applications to validate assays using well-annotated human biospecimens. Projects require multidisciplinary collaboration and aim to develop clinically useful assays for cancer prevention, control, and therapy guidance.
Eligible applicants include state, county, city, and tribal governments; public and private higher education institutions; nonprofits; for-profit organizations including small businesses; and various other specified organizations. Detailed eligibility includes a broad range of government and nonprof
